Insider Trading March 23, 2026

Thryv Director Buys $13,000 in Shares as Company Repositions Toward Higher-Value Customers

Orfanos Lou adds 5,000 common shares on March 18, 2026 amid a year of sharp share declines and mixed fourth-quarter results

By Derek Hwang THRY
Thryv Director Buys $13,000 in Shares as Company Repositions Toward Higher-Value Customers
THRY

Thryv Holdings director Orfanos Lou purchased 5,000 shares on March 18, 2026 at $2.60 per share, a $13,000 transaction that brings his direct holdings to 16,035 shares. The move comes after an 82% year-over-year slide in Thryv's stock, which has since traded up to $2.97, and follows a fourth-quarter 2025 earnings report that missed EPS expectations while slightly topping revenue estimates. Analysts maintain differing views on fair value with price targets in the $4 to $6 range.

Key Points

  • Insider purchase: Director Orfanos Lou bought 5,000 shares at $2.60 on March 18, 2026, bringing his direct ownership to 16,035 shares - relevant to investors tracking insider confidence.
  • Mixed quarterly results: Q4 2025 EPS of -$0.22 missed the $0.18 forecast by -222.22%, while revenue of $191.62 million slightly exceeded the $191.25 million estimate.
  • Strategic pivot and analyst views: Thryv is shifting toward customers with $400+ monthly revenue and launching the Market Sell Grow AI-enabled platform; analyst price targets range from $4 to $6 with differing ratings from Craig-Hallum and Needham.

Director Orfanos Lou of Thryv Holdings Inc (NASDAQ:THRY) purchased 5,000 shares of the company’s common stock on March 18, 2026, according to a filing. The shares were acquired at $2.60 each, for a total outlay of $13,000. After the transaction, Lou directly owns 16,035 shares of Thryv.

The purchase arrives after a period of steep share-price erosion: Thryv’s stock has fallen roughly 82% over the past year, although recent trading has seen the price rebound to $2.97. InvestingPro analysis cited in company materials indicates the stock may be undervalued at current levels, with analyst price targets reported in a $4 to $6 range.


Latest financials and strategic update

Thryv’s reported fourth-quarter 2025 results included an earnings-per-share (EPS) figure of -$0.22, missing the consensus forecast of $0.18. That shortfall represents a surprise of -222.22% relative to expectations. Revenue for the quarter was $191.62 million, narrowly ahead of the forecasted $191.25 million.

The company has signaled a strategic shift toward higher-value customers, concentrating on those that generate at least $400 in monthly revenue. As part of that pivot, Thryv is rolling out Market Sell Grow, an AI-enabled platform intended to support the focus on more lucrative clients.

Analysts have reacted to the results and strategic refocus with adjustments to their price targets. Craig-Hallum lowered its target to $4.00 while keeping a Hold rating. Needham reduced its price target to $6.00 but retained a Buy rating, noting that Thryv’s most recent results were broadly in line with expectations but flagging weak customer growth as a concern.


Research resources

For investors seeking additional valuation context and a deeper look at Thryv’s prospects, a Pro Research Report is available on InvestingPro for THRY and more than 1,400 other U.S. equities, according to company materials.

Risks

  • Earnings risk: The significant EPS miss in Q4 2025 highlights execution or margin pressures that could weigh on investor sentiment and affect market valuation - impacting the software and small-business services sectors.
  • Customer growth uncertainty: Needham explicitly cited weak customer growth as a concern, which could slow revenue expansion and limit the effectiveness of the company’s pivot toward higher-value customers - relevant to marketing services and SMB software markets.
  • Limited signaling from purchase size: While insider buying can be interpreted as a vote of confidence, the $13,000 transaction is relatively modest and may have limited informational value for broader market participants - relevant to equity investors and market observers.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026